Johnson & Johnson has presented interim data from a phase 1/2a clinical trial of a single-dose coronavirus vaccine. The drug induced an immune response and was well tolerated. Neutralizing antibodies were detected in more than 90% of subjects on day 29 and in 100% of participants aged 18-55 by day 57. Immune response data for study participants over the age of 65, as well as phase 3 data, will be available in late January.